Developer docs
API playgroundTry for free, no card

Search company profiles

iHealthScreen

Full company profile

uuid0004tbf

Namestring
iHealthScreen
Legal namestring
iHealthScreen Inc.
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRichmond Hill, United States
HQ citystring
Richmond Hill
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI retinal screening, diabetic retinopathy detection, ophthalmic diagnostic software, medical imaging AI, predictive health analytics
Industry3 codes
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
NAICS code3 codes
  • Ophthalmic Goods Manufacturing339115
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Offices of Optometrists62132
SIC code2 codes
  • Ophthalmic Goods3851
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ophthalmic AI Screening Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Per-Test Screening Fees
TypeSubscription Recurring
Description

B2B revenue from healthcare providers and clinics using the iPredict screening system on a per-test or subscription basis. Each screening test priced at approximately $50 per patient.

2EHR and Telemedicine Platform Services
TypeLicensing Royalties
Description

Revenue generated from integration and licensing of the iPredict and MyHealth EHR/telemedicine platforms to healthcare facilities.

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Per-Test Screening — ~$50 per patient screened
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Approximate $50 per screening test for healthcare providers and clinics.

2Enterprise Subscription — quote-based pricing for high-volume healthcare providers
ModelSubscriptionBilling cadenceAnnual
Notes

Volume-based subscription for large healthcare systems and hospitals. Pricing not publicly disclosed.

GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1iPredict
Description

AI-based eye screening system for automated diagnosis of AMD, DR, and glaucoma; also includes prediction apps for diabetes, stroke, and heart attack

ihealthscreen.org
+3 more records
Core offering1 text field

iHealthScreen develops and sells the iPredict AI software platform, which analyzes retinal color fundus photographs to automatically screen for three blinding eye diseases — Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma — simultaneously, delivering diagnostic results in under 5 minutes with reported accuracy above 95%. The platform also includes risk prediction tools for stroke, heart attack, and diabetes, EHR solutions (iPredict and MyHealth), telemedicine capabilities, and specialized retinal image analyzers (RePPA, ReVA, OCT Inspector) sold to healthcare providers, hospital systems, and government screening programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 95%+ screening accuracy for DR, AMD, and glaucoma detection
+3 more records
Product overview1 text field

iHealthScreen offers a unified AI-driven healthcare platform centered on the iPredict system, which provides automated screening for three blinding eye diseases (Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma) along with health risk prediction tools for stroke, heart attack, and diabetes. The platform includes EHR solutions (iPredict for USA, MyHealth for Bangladesh), telemedicine capabilities, and specialized image analysis tools (RePPA, ReVA, OCT Inspector) that process retinal images using deep learning algorithms to deliver diagnostic results in under 60 seconds.

Product and service13 records
1iPredict
CategoryAI-based eye disease screening platform
Description

AI-based telemedicine platform providing fully automated screening for Diabetic Retinopathy, AMD, and Glaucoma plus health risk prediction for stroke, heart attack, and diabetes. Processes retinal images and delivers diagnostic results in under 60 seconds; CE certified and FDA 510(k) submitted.

2iPredict DR (Diabetic Retinopathy)
CategoryAI-based eye disease screening
Description

Automated AI system for early diagnosis of Diabetic Retinopathy using retinal imaging. Reports up to 98.48% accuracy, 97.32% sensitivity, and 98.75% specificity for referable DR; FDA 510(k) submission in progress.

3iPredict AMD (Age-related Macular Degeneration)
CategoryAI-based eye disease screening
Description

Automated AI system for screening Age-related Macular Degeneration in adults 50+. Reports 99.2% accuracy with 98.9% sensitivity and 99.5% specificity for referrable AMD; FDA 510(k) submitted.

4iPredict Glaucoma
CategoryAI-based eye disease screening
Description

Automated AI system for glaucoma suspect detection based on abnormal optic discs. Reports 89.67% accuracy with 83.33% sensitivity and 93.89% specificity; TGA, MHRA, and UAE Health approved.

5iPredict Diabetes
CategoryHealth risk prediction
Description

AI-powered risk prediction tool that foretells the risk of diabetes and provides hassle-free information to patients and doctors with simple results and easy-to-understand suggestions.

6iPredict Stroke
CategoryHealth risk prediction
Description

AI-based stroke risk prediction tool that foretells the risk of stroke and provides information in a hassle-free manner to both patient and doctor.

7iPredict Heart Attack
CategoryHealth risk prediction
Description

AI-based myocardial infarction (heart attack) risk prediction tool that foretells heart attack risk and provides information to patients and doctors.

8Electronic Health Record (EHR) Solutions
CategoryEHR and clinical workflow software
Description

Digital version of traditional paper-based medical records with telemedicine integration, digital prescription, video consultation, and patient data history management. Available as iPredict (USA) and MyHealth (Bangladesh).

9Telemedicine Platform
CategoryTelemedicine software
Description

Telemedicine app enabling online appointments, video/audio consultations with doctors, online prescriptions, and specialist search. Connects patients with healthcare providers remotely.

10RePPA (Retinal Pathology Progression Analyzer)
CategoryRetinal image analysis software
Description

Image analysis tool for analyzing retinal pathology progression in Diabetic Retinopathy, AMD, and other eye diseases. Features image calibration, vessel/optic disk analysis, drusen analysis, and two-image registration at different times.

11ReVA (Retinal Vessel Analyzer)
CategoryRetinal image analysis software
Description

Automated retinal blood vessel analysis tool to determine individual risk for systemic diseases. Features optic disc detection, blood vessel detection, vessel width measurement, image grading, and CRAE/CRVE computation.

12OCT Inspector
CategoryRetinal image analysis software
Description

Optical Coherence Tomography analysis tool for finding and monitoring retinal diseases through automated segmentation of retinal layers in 2D and 3D from SD-OCT images.

13MyHealth
CategoryTelemedicine and EHR software
Description

Telemedicine platform variant deployed in Bangladesh, offering telemedicine services, AI-based eye disease screening, and electronic health records for the Bangladesh market.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration with Mount Sinai Hospital (New York Eye and Ear Infirmary) for validation of the AI-based screening system. Mount Sinai serves as a key clinical validation site in the USA, having screened patients for DR, AMD, and glaucoma using the iPredict system.

2Diabetic Association of Bangladesh (BADAS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with BADAS for large-scale diabetic eye disease screening in Bangladesh, targeting 5 million diabetic patients. This is a flagship deployment partnership enabling population-level screening in a high-need geography.

3Bangladesh Diabetes Society
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative screening partnership with Bangladesh Diabetes Society to screen 5 million diabetics across Bangladesh for diabetic retinopathy and other eye diseases, leveraging the iPredict AI screening platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Sister concern and strategic partner operating the Bangladesh operations, supporting the deployment of screening programs and market expansion in the Bangladesh region.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Has published foundational research on retinal AI for systemic disease prediction (cardiovascular risk from fundus images). A large incumbent with research overlap that could enter commercial ophthalmic AI screening.

TypeEmerging player
Description

Specialist in AI-based medical image analysis including retinal OCT and fundus image quantification. Comparable in applying deep learning to retinal image analysis for clinical decision support.

TypeBroad incumbent
Description

Premium retinal imaging and OCT systems used by ophthalmologists worldwide with emerging AI-enabled diagnostic tools. Comparable as an incumbent imaging platform increasingly augmented with AI screening.

TypeBroad incumbent
Description

Major ophthalmic imaging hardware and software provider (fundus cameras, OCT) integrating AI screening into its devices. Comparable in retinal imaging workflows with growing AI-screening capability competitive with iPredict.

5Carl Zeiss Meditec
TypeBroad incumbent
Description

Global ophthalmic device leader producing fundus cameras, OCT, and integrated diagnostic platforms. Comparable as a broad incumbent in ophthalmic imaging where AI screening increasingly sits on top of their hardware.

6Digital Diagnostics (IDx-DR)
TypeDirect peer
Description

Pioneer in autonomous AI diagnosis of diabetic retinopathy; IDx-DR was the first FDA-cleared autonomous AI diagnostic in any specialty of medicine (acquired by GE HealthCare). Directly comparable in target disease (DR) and autonomous-screening positioning.

TypeDirect peer
Description

AI-based retinal image analysis platform for DR, AMD, and glaucoma screening sold to optometrists and primary care in Europe and select international markets. Closely comparable in product breadth and customer base.

TypeEmerging player
Description

AI company using retinal images to predict systemic disease risk (cardiovascular, kidney, age-related conditions). Comparable in expanding retinal imaging beyond ophthalmology into systemic-disease prediction.

TypeDirect peer
Description

FDA-cleared autonomous AI for DR screening using retinal imaging, with similar single-image, point-of-care workflow in primary-care settings. Direct competitor for US and international screening deployments.

TypeDirect peer
Description

FDA-cleared AI platform for autonomous detection of DR and other retinal diseases, competing head-to-head with iHealthScreen in primary-care DR screening workflows globally.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iHealthScreen

Ophthalmic AI Screening Softwareihealthscreen.org

iHealthScreen firmographics

Firmographics
Name
iHealthScreen
Legal name
iHealthScreen Inc.
Website
https://ihealthscreen.org
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

iHealthScreen industry classification

Industry
Product category
Ophthalmic AI Screening Software
NAICS
Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Optometrists (62132)
SIC
Ophthalmic Goods (3851), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)

Keywords

  • AI retinal screening
  • Diabetic retinopathy detection
  • Ophthalmic diagnostic software
  • Medical imaging AI
  • Predictive health analytics

Where iHealthScreen is headquartered

Location

Headquarters

HQ city
Richmond Hill
HQ country
United States
HQ region
North America

Offices4 records

Markets served

iHealthScreen business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Per-Test Screening Fees: B2B revenue from healthcare providers and clinics using the iPredict screening system on a per-test or subscription basis. Each screening test priced at approximately $50 per patient.
  2. EHR and Telemedicine Platform Services: Revenue generated from integration and licensing of the iPredict and MyHealth EHR/telemedicine platforms to healthcare facilities.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPer-Test Screening — ~$50 per patient screened
SubscriptionAnnualEnterprise Subscription — quote-based pricing for high-volume healthcare providers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

iHealthScreen product offering

Product offering

Core offering

iHealthScreen develops and sells the iPredict AI software platform, which analyzes retinal color fundus photographs to automatically screen for three blinding eye diseases — Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma — simultaneously, delivering diagnostic results in under 5 minutes with reported accuracy above 95%. The platform also includes risk prediction tools for stroke, heart attack, and diabetes, EHR solutions (iPredict and MyHealth), telemedicine capabilities, and specialized retinal image analyzers (RePPA, ReVA, OCT Inspector) sold to healthcare providers, hospital systems, and government screening programs.

Product overview

iHealthScreen offers a unified AI-driven healthcare platform centered on the iPredict system, which provides automated screening for three blinding eye diseases (Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma) along with health risk prediction tools for stroke, heart attack, and diabetes. The platform includes EHR solutions (iPredict for USA, MyHealth for Bangladesh), telemedicine capabilities, and specialized image analysis tools (RePPA, ReVA, OCT Inspector) that process retinal images using deep learning algorithms to deliver diagnostic results in under 60 seconds.

Differentiator

Problem solved

Functional benefit

Brands

  • iPredict: AI-based eye screening system for automated diagnosis of AMD, DR, and glaucoma; also includes prediction apps for diabetes, stroke, and heart attack
  • MyHealth
  • RePPA
  • ReVA

Products and services

  • iPredict AI-based telemedicine platform providing fully automated screening for Diabetic Retinopathy, AMD, and Glaucoma plus health risk prediction for stroke, heart attack, and diabetes. Processes retinal images and delivers diagnostic results in under 60 seconds; CE certified and FDA 510(k) submitted.
  • iPredict DR (Diabetic Retinopathy) Automated AI system for early diagnosis of Diabetic Retinopathy using retinal imaging. Reports up to 98.48% accuracy, 97.32% sensitivity, and 98.75% specificity for referable DR; FDA 510(k) submission in progress.
  • iPredict AMD (Age-related Macular Degeneration) Automated AI system for screening Age-related Macular Degeneration in adults 50+. Reports 99.2% accuracy with 98.9% sensitivity and 99.5% specificity for referrable AMD; FDA 510(k) submitted.
  • iPredict Glaucoma Automated AI system for glaucoma suspect detection based on abnormal optic discs. Reports 89.67% accuracy with 83.33% sensitivity and 93.89% specificity; TGA, MHRA, and UAE Health approved.
  • iPredict Diabetes AI-powered risk prediction tool that foretells the risk of diabetes and provides hassle-free information to patients and doctors with simple results and easy-to-understand suggestions.
  • iPredict Stroke AI-based stroke risk prediction tool that foretells the risk of stroke and provides information in a hassle-free manner to both patient and doctor.
  • iPredict Heart Attack AI-based myocardial infarction (heart attack) risk prediction tool that foretells heart attack risk and provides information to patients and doctors.
  • Electronic Health Record (EHR) Solutions Digital version of traditional paper-based medical records with telemedicine integration, digital prescription, video consultation, and patient data history management. Available as iPredict (USA) and MyHealth (Bangladesh).
  • Telemedicine Platform Telemedicine app enabling online appointments, video/audio consultations with doctors, online prescriptions, and specialist search. Connects patients with healthcare providers remotely.
  • RePPA (Retinal Pathology Progression Analyzer) Image analysis tool for analyzing retinal pathology progression in Diabetic Retinopathy, AMD, and other eye diseases. Features image calibration, vessel/optic disk analysis, drusen analysis, and two-image registration at different times.
  • ReVA (Retinal Vessel Analyzer) Automated retinal blood vessel analysis tool to determine individual risk for systemic diseases. Features optic disc detection, blood vessel detection, vessel width measurement, image grading, and CRAE/CRVE computation.
  • OCT Inspector Optical Coherence Tomography analysis tool for finding and monitoring retinal diseases through automated segmentation of retinal layers in 2D and 3D from SD-OCT images.
  • MyHealth Telemedicine platform variant deployed in Bangladesh, offering telemedicine services, AI-based eye disease screening, and electronic health records for the Bangladesh market.

Quantifiable outcome

  • 95%+ screening accuracy for DR, AMD, and glaucoma detection
  • +3 more outcomes

Companies that use iHealthScreen

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

iHealthScreen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature3 records

iHealthScreen partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Mount Sinai Hospital — New York Eye and Ear InfirmarycoreStrategic or Co-development PartnerClinical trial collaboration with Mount Sinai Hospital (New York Eye and Ear Infirmary) for validation of the AI-based screening system. Mount Sinai serves as a key clinical validation site in the USA, having screened patients for DR, AMD, and glaucoma using the iPredict system.
  • Diabetic Association of Bangladesh (BADAS)coreStrategic or Co-development PartnerPartnership with BADAS for large-scale diabetic eye disease screening in Bangladesh, targeting 5 million diabetic patients. This is a flagship deployment partnership enabling population-level screening in a high-need geography.
  • Bangladesh Diabetes SocietycoreStrategic or Co-development PartnerCollaborative screening partnership with Bangladesh Diabetes Society to screen 5 million diabetics across Bangladesh for diabetic retinopathy and other eye diseases, leveraging the iPredict AI screening platform.
  • Innovation Place Bangladesh (IPB)minorStrategic or Co-development PartnerSister concern and strategic partner operating the Bangladesh operations, supporting the deployment of screening programs and market expansion in the Bangladesh region.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

iHealthScreen competitors and assessment

Company assessment

Broad incumbents

  • Google Health (Retinal AI): Has published foundational research on retinal AI for systemic disease prediction (cardiovascular risk from fundus images). A large incumbent with research overlap that could enter commercial ophthalmic AI screening.
  • Heidelberg Engineering: Premium retinal imaging and OCT systems used by ophthalmologists worldwide with emerging AI-enabled diagnostic tools. Comparable as an incumbent imaging platform increasingly augmented with AI screening.
  • Topcon Healthcare: Major ophthalmic imaging hardware and software provider (fundus cameras, OCT) integrating AI screening into its devices. Comparable in retinal imaging workflows with growing AI-screening capability competitive with iPredict.
  • Carl Zeiss Meditec: Global ophthalmic device leader producing fundus cameras, OCT, and integrated diagnostic platforms. Comparable as a broad incumbent in ophthalmic imaging where AI screening increasingly sits on top of their hardware.

Emerging players

  • Thirona: Specialist in AI-based medical image analysis including retinal OCT and fundus image quantification. Comparable in applying deep learning to retinal image analysis for clinical decision support.
  • Mediwhale: AI company using retinal images to predict systemic disease risk (cardiovascular, kidney, age-related conditions). Comparable in expanding retinal imaging beyond ophthalmology into systemic-disease prediction.

Direct peers

  • Digital Diagnostics (IDx-DR): Pioneer in autonomous AI diagnosis of diabetic retinopathy; IDx-DR was the first FDA-cleared autonomous AI diagnostic in any specialty of medicine (acquired by GE HealthCare). Directly comparable in target disease (DR) and autonomous-screening positioning.
  • RetinaLyze: AI-based retinal image analysis platform for DR, AMD, and glaucoma screening sold to optometrists and primary care in Europe and select international markets. Closely comparable in product breadth and customer base.
  • AEYE Health: FDA-cleared autonomous AI for DR screening using retinal imaging, with similar single-image, point-of-care workflow in primary-care settings. Direct competitor for US and international screening deployments.
  • Eyenuk (EyeArt): FDA-cleared AI platform for autonomous detection of DR and other retinal diseases, competing head-to-head with iHealthScreen in primary-care DR screening workflows globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

iHealthScreen social profiles

Digital presence

iHealthScreen compliance and trust

Trust signal

Compliance6 records

iHealthScreen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iHealthScreen leadership team

Management profile

Number of profiles

Profiles6 records

iHealthScreen subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

iHealthScreen funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iHealthScreen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iHealthScreen

What does iHealthScreen do?

iHealthScreen develops and sells the iPredict AI software platform, which analyzes retinal color fundus photographs to automatically screen for three blinding eye diseases — Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma — simultaneously, delivering diagnostic results in under 5 minutes with reported accuracy above 95%. The platform also includes risk prediction tools for stroke, heart attack, and diabetes, EHR solutions (iPredict and MyHealth), telemedicine capabilities, and specialized retinal image analyzers (RePPA, ReVA, OCT Inspector) sold to healthcare providers, hospital systems, and government screening programs.

Is iHealthScreen a public or private company?

iHealthScreen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was iHealthScreen founded?

iHealthScreen was founded in 2015. It employs 11 to 50 people.

Where is iHealthScreen based?

iHealthScreen is headquartered in Richmond Hill, United States, in the North America region.

How does iHealthScreen make money?

Two revenue lines are on record. Per-Test Screening Fees are the primary driver. The others are EHR and Telemedicine Platform Services.

Who are iHealthScreen's main competitors?

Broad incumbents on record are Google Health (Retinal AI), Heidelberg Engineering, Topcon Healthcare and Carl Zeiss Meditec. Emerging players are Thirona and Mediwhale. Direct peers are Digital Diagnostics (IDx-DR), RetinaLyze, AEYE Health and Eyenuk (EyeArt).

Does iHealthScreen have an API?

No public API is recorded for iHealthScreen.

What industry is iHealthScreen in?

iHealthScreen's product category is Ophthalmic AI Screening Software. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkFDA clears iHealthScreen’s AI diabetic retinopathy screening softwareThe US Food and Drug Administration has granted clearance to iHealthScreen's iPredict-DR, an AI-based software that screens for diabetic retinopathy by analyzing colour retinal fundus images captured by the iCare DRSplus camera. The clinical validation trial demonstrated the SaMD's diagnostic performance, safety, and usability met FDA requirements. New York-based iHealthScreen now plans to pursue additional FDA clearances for detecting age-related macular degeneration, glaucoma, hypertensive retinopathy, and cardiovascular disease risk.FierceBiotechIHealthScreen nabs FDA nod for AI-backed dx to spot mild diabetic retinopathyIHealthScreen, a Richmond Hill, New York-based medical device company, has received FDA 510(k) clearance for its AI-powered diagnostic system iPredict-DR that detects mild diabetic retinopathy in undiagnosed diabetic adults. The non-invasive system uses AI to review retinal fundus images captured by the iCare DRSplus camera and is designed to be operated by minimally skilled healthcare workers in primary care and community settings. The company, founded in 2015, is also pursuing FDA clearances for detecting age-related macular degeneration, glaucoma, hypertensive retinopathy, and cardiovascular disease risk.MorningstariHealthScreen Receives U.S. FDA 510(k) Clearance (K253704) for iPredict-DR, an AI-Powered Software for Automated Diabetic Retinopathy ScreeningiHealthScreen received FDA 510(k) clearance (K253704) for iPredict-DR, an AI-powered software that automatically detects mild diabetic retinopathy in adults with diabetes. The clearance was supported by a clinical validation trial, and the software is now commercially available in the U.S. The company is seeking distribution partners and advancing clearances for other retinal conditions.StartEngineInvest in iHealthScreeniHealthScreen is seeking investment to commercialize its AI-driven retinal imaging software for screening diseases like AMD, diabetic retinopathy, and glaucoma, having already secured CE certification and approvals in Australia and the UAE. The company has obtained $2.7 million in NIH funding and established strategic partnerships with entities including iCare Finland and Burjeel Hospital UAE while awaiting FDA clearances.ForbesSeeing The Future: Artificial Intelligence For Age-Related Macular DegenerationAI-based screening systems, such as iHealthScreen's iPredict, can predict risk of late-stage age-related macular degeneration from retinal images. The system achieved 86% and 84% accuracy in trials, with FDA clearance expected by end of 2023. Early detection could improve patient outcomes and prevent irreversible vision loss.GlobeNewswireAI-Based Health Screening Company iHealthScreen Announces Q&A WebinariHealthScreen will host a Q&A webinar on July 11 at 9 a.m. PDT with CEO Alauddin Bhuiyan to discuss its AI-based health screening software. The company holds CE certification and Australian and UAE approvals for AMD, diabetic retinopathy, and glaucoma screening, and is running an equity crowdfunding campaign on StartEngine.GlobeNewswireAI-Based Health Screening Company iHealthScreen Reaches $150K in InvestmentsiHealthScreen raised $150,000 on StartEngine, bringing its total seed and NIH funding to over $3 million. The company's retinal imaging system is CE-certified and approved in Australia and the UAE for AMD, diabetic retinopathy, and glaucoma screening. It is seeking additional research grants.GlobeNewswireAI-Based Health Screening Company iHealthScreen Reaches $150K in InvestmentsAI-based health screening company iHealthScreen announced the raising of $150,000 in investments via StartEngine, bringing its total funding to over $3 million when combined with previous seed and NIH grants. The company utilizes retinal imaging technology for early detection of eye diseases and has secured regulatory approvals in the EU, Australia, and UAE. This financing supports ongoing operations as the firm expands into primary care settings in markets including the U.S., Bangladesh, and the UAE.